The stimulative effects of endogenous opioids on endothelial cell proliferation, migration and angiogenesis in vitro

European Journal of Pharmacology

Volumn 628, Issue 1-3, 2010, Pages 42-50

  Dai, Xu ^a,b   Song, Hong jin ^a   Cui, Shi gang ^a,b   Wang, Ting ^a,b   Liu, Qian ^a   Wang, Rui ^a,b  

^a Institute of Biochemistry and Molecular Biology   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Angiogenesis; Deltorphin I; Endomorphin 1; Endomorphin 2; HUVEC

Indexed keywords

DELTORPHIN; DELTORPHIN 1; ENDOMORPHIN 1; ENDOMORPHIN 2; ENDORPHIN; NALOXONE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PRIORITY JOURNAL; UMBILICAL VEIN;

AMINO ACID SEQUENCE; ANALGESICS, OPIOID; CELL ADHESION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

EID: 73949143036     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.035     Document Type: Article

References (54)

1. Axelrad T.W., Deo D.D., Ottino P., Van Kirk J., Bazan N.G., Bazan H.E., and Hunt J.D. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. Faseb. J. 18 (2004) 568-570
2. Balasubramanian S., Ramakrishnan S., Charboneau R., Wang J., Barke R.A., and Roy S. Morphine sulfate inhibits hypoxia-induced vascular endothelial growth factor expression in endothelial cells and cardiac myocytes. J. Mol. Cell. Cardiol. 33 (2001) 2179-2187
3. Baumgartner I., Pieczek A., Manor O., Blair R., Kearney M., Walsh K., and Isner J.M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97 (1998) 1114-1123
4. Blebea J., Mazo J.E., Kihara T.K., Vu J.H., McLaughlin P.J., Atnip R.G., and Zagon I.S. Opioid growth factor modulates angiogenesis. J. Vasc. Surg. 32 (2000) 364-373
5. Blebea J., Vu J.H., Assadnia S., McLaughlin P.J., Atnip R.G., and Zagon I.S. Differential effects of vascular growth factors on arterial and venous angiogenesis. J. Vasc. Surg. 35 (2002) 532-538
6. Bodnar R.J., and Klein G.E. Endogenous opiates and behavior: 2005. Peptides 27 (2006) 3391-3478
7. Cadet P., Bilfinger T.V., Fimiani C., Peter D., and Stefano G.B. Human vascular and cardiac endothelia express mu opiate receptor transcripts. Endothelium 7 (2000) 185-191
8. Cadet P., Mantione K.J., Bilfinger T.V., and Stefano G.B. Differential expression of the human mu opiate receptor from different primary vascular endothelial cells. Med. Sci. Monit. 10 (2004) BR351-BR355
9. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
10. Chen C., Farooqui M., and Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr. Neurovasc. Res. 3 (2006) 171-180
11. Clark R.A., Folkvord J.M., and Nielsen L.D. Either exogenous or endogenous fibronectin can promote adherence of human endothelial cells. J. Cell Sci. 82 (1986) 263-280
12. Dai X., Cui S.G., Wang T., Liu Q., Song H.J., and Wang R. Endogenous opioid peptides, endomorphin-1 and -2 and deltorphin I, stimulate angiogenesis in the CAM assay. Eur. J. Pharmacol. 579 (2008) 269-275
13. Davis G.E., Black S.M., and Bayless K.J. Capillary morphogenesis during human endothelial cell invasion of three-dimensional collagen matrices. In Vitro Cell. Dev. Biol. Anim. 36 (2000) 513-519
14. Dermitzaki E., Chatzaki E., Gravanis A., and Margioris A.N. Opioids transiently prevent activation of apoptotic mechanisms following short periods of serum withdrawal. J. Neurochem. 74 (2000) 960-969
15. Downey J.M., Davis A.M., and Cohen M.V. Signaling pathways in ischemic preconditioning. Heart Fail. Rev. 12 (2007) 181-188
16. Ekstrand A.J., Cao R., Bjorndahl M., Nystrom S., Jonsson-Rylander A.C., Hassani H., Hallberg B., Nordlander M., and Cao Y. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6033-6038
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
18. Gomez-Flores R., Rice K.C., Zhang X., and Weber R.J. Increased tumor necrosis factor-alpha and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the delta-opioid agonist SNC 80. Life Sci. 68 (2001) 2675-2684
19. Gupta K., Kshirsagar S., Chang L., Schwartz R., Law P.Y., Yee D., and Hebbel R.P. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 62 (2002) 4491-4498
20. Harimaya Y., Koizumi K., Andoh T., Nojima H., Kuraishi Y., and Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 187 (2002) 121-127
21. Hayashi T., Tsao L.I., and Su T.P. Antiapoptotic and cytotoxic properties of delta opioid peptide (D-Ala(2), D-Leu(5))enkephalin in PC12 cells. Synapse 43 (2002) 86-94
22. Hu S., Chao C.C., Hegg C.C., Thayer S., and Peterson P.K. Morphine inhibits human microglial cell production of, and migration towards, RANTES. J. Psychopharmacol. 14 (2000) 238-243
23. Iida T., Mine S., Fujimoto H., Suzuki K., Minami Y., and Tanaka Y. Hypoxia-inducible factor-1alpha induces cell cycle arrest of endothelial cells. Genes Cells 7 (2002) 143-149
24. Kitlinska J., Abe K., Kuo L., Pons J., Yu M., Li L., Tilan J., Everhart L., Lee E.W., Zukowska Z., and Toretsky J.A. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res. 65 (2005) 1719-1728
25. Klagsbrun M., and D'Amore P.A. Regulators of angiogenesis. Annu. Rev. Physiol. 53 (1991) 217-239
26. Korzh A., Keren O., Gafni M., Bar-Josef H., and Sarne Y. Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell. Brain Res. 1189 (2008) 23-32
27. Krajnik M., Zylicz Z., Finlay I., Luczak J., and van Sorge A.A. Potential uses of topical opioids in palliative care-report of 6 cases. Pain 80 (1999) 121-125
28. Kuiper R.A., Schellens J.H., Blijham G.H., Beijnen J.H., and Voest E.E. Clinical research on antiangiogenic therapy. Pharmacol. Res. 37 (1998) 1-16
29. Li M.H., Miao Z.H., Tan W.F., Yue J.M., Zhang C., Lin L.P., Zhang X.W., and Ding J. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin. Cancer Res. 10 (2004) 8266-8274
30. Losordo D.W., Vale P.R., Symes J.F., Dunnington C.H., Esakof D.D., Maysky M., Ashare A.B., Lathi K., and Isner J.M. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98 (1998) 2800-2804
31. Mack C.A., Patel S.R., Schwarz E.A., Zanzonico P., Hahn R.T., Ilercil A., Devereux R.B., Goldsmith S.J., Christian T.F., Sanborn T.A., Kovesdi I., Hackett N., Isom O.W., Crystal R.G., and Rosengart T.K. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thorac. Cardiovasc. Surg. 115 (1998) 176-177 discussion
32. Neudeck B.L., and Loeb J.M. Endomorphin-1 alters interleukin-8 secretion in Caco-2 cells via a receptor mediated process. Immunol. Lett. 84 (2002) 217-221
33. Otani A., Tagaki H., Suzuma K., and Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 82 (1998) 619-628
34. Pal S., Wu J., Murray J.K., Gellman S.H., Wozniak M.A., Keely P.J., Boyer M.E., Gomez T.M., Hasso S.M., Fallon J.F., and Bresnick E.H. An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis. J. Cell Biol. 174 (2006) 1047-1058
35. Pan S., An P., Zhang R., He X., Yin G., and Min W. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol. Cell. Biol. 22 (2002) 7512-7523
36. Papapetropoulos A., Garcia-Cardena G., Madri J.A., and Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100 (1997) 3131-3139
37. Poonawala T., Levay-Young B.K., Hebbel R.P., and Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 13 (2005) 165-174
38. Puduvalli V.K. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat. Res. 117 (2004) 307-336
39. Ribatti D., Conconi M.T., and Nussdorfer G.G. Nonclassic endogenous novel (corrected) regulators of angiogenesis. Pharmacol. Rev. 59 (2007) 185-205
40. Rosengart T.K., Lee L.Y., Patel S.R., Sanborn T.A., Parikh M., Bergman G.W., Hachamovitch R., Szulc M., Kligfield P.D., Okin P.M., Hahn R.T., Devereux R.B., Post M.R., Hackett N.R., Foster T., Grasso T.M., Lesser M.L., Isom O.W., and Crystal R.G. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100 (1999) 468-474
41. Schumacher B., Pecher P., von Specht B.U., and Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97 (1998) 645-650
42. Singleton P.A., Lingen M.W., Fekete M.J., Garcia J.G., and Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc. Res. 72 (2006) 3-11
43. Stefano G.B., Neenan K., Cadet P., Magazine H., and Bilfinger T.V. Ischemic preconditioning - an opiate constitutive nitric oxide molecular hypothesis. Med. Sci. Monit. 7 (2001) 1357-1375
44. Stefano G.B., Salzet M., Hughes T.K., and Bilfinger T.V. Delta2 opioid receptor subtype on human vascular endothelium uncouples morphine stimulated nitric oxide release. Int. J. Cardiol. 64 Suppl 1 (1998) S43-S51
45. Tegeder I., and Geisslinger G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol. Rev. 56 (2004) 351-369
46. Tortorella L.L., Milasincic D.J., and Pilch P.F. Critical proliferation-independent window for basic fibroblast growth factor repression of myogenesis via the p42/p44 MAPK signaling pathway. J. Biol. Chem. 276 (2001) 13709-13717
47. Tsuneki H., Ma E.L., Kobayashi S., Sekizaki N., Maekawa K., Sasaoka T., Wang M.W., and Kimura I. Antiangiogenic activity of beta-eudesmol in vitro and in vivo. Eur. J. Pharmacol. 512 (2005) 105-115
48. Tsurumi Y., Kearney M., Chen D., Silver M., Takeshita S., Yang J., Symes J.F., and Isner J.M. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 96 (1997) II-382-II-388
49. Vujic V., Stanojevic S., and Dimitrijevic M. Methionine-enkephalin stimulates hydrogen peroxide and nitric oxide production in rat peritoneal macrophages: interaction of mu, delta and kappa opioid receptors. Neuroimmunomodulation 11 (2004) 392-403
50. Wenk H.N., and Honda C.N. Immunohistochemical localization of delta opioid receptors in peripheral tissues. J. Comp. Neurol. 408 (1999) 567-579
51. Wu N., Ren W.H., Huo X.F., Chen Q., and Wang R. Effects of endomorphins and their analogs on cardiovascular system. Yao. Xue. Xue. Bao. 36 (2001) 241-245
52. Zagon I.S., Rahn K.A., and McLaughlin P.J. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides 41 (2007) 441-452
53. Zhao M., Wang H.X., Yang J., Su Y.H., Su R.J., and Wong T.M. delta-Opioid receptor stimulation enhances the growth of neonatal rat ventricular myocytes via the extracellular signal-regulated kinase pathway. Clin. Exp. Pharmacol. Physiol. 35 (2008) 97-102
54. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., and Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99 (1997) 2625-2634